Fiber Therapy Tablet
NDC 49035-147
Product Information
Fiber Therapy (calcium polycarbophil) is a OTC MONOGRAPH DRUG-approved product labeled by Wal-mart Stores, Inc.. Polycarbophil is used to treat constipation. It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 49035-147 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
G147
Code Structure Chart
Product Details
What is NDC 49035-147?
What are the uses of this product?
What are Active Ingredients of this product?
- CALCIUM POLYCARBOPHIL 625 mg/1 - synthetic, loosely cross-linked, hydrophilic resin of the polycarboxylic type; marketed as a stool normalizer; used in the treatment of both constipation & diarrhea
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CALCIUM POLYCARBOPHIL (UNII: 8F049NKY49)
- POLYCARBOPHIL (UNII: W25LM17A4W) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CALCIUM CARBONATE (UNII: H0G9379FGK)
- CARAMEL (UNII: T9D99G2B1R)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- CROSPOVIDONE, UNSPECIFIED (UNII: 2S7830E561)
- HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)
- SODIUM LAURYL SULFATE (UNII: 368GB5141J)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 308934 - calcium polycarbophil 625 MG Oral Tablet
- RxCUI: 308934 - calcium polycarbophil 625 MG (as polycarbophil 500 MG) Oral Tablet
* Please review the full disclaimer at the bottom of this page.